464 related articles for article (PubMed ID: 38390935)
21. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
Front Immunol; 2021; 12():691741. PubMed ID: 34211478
[TBL] [Abstract][Full Text] [Related]
22. Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.
Mata M; Vera JF; Gerken C; Rooney CM; Miller T; Pfent C; Wang LL; Wilson-Robles HM; Gottschalk S
J Immunother; 2014 Oct; 37(8):407-15. PubMed ID: 25198528
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
24. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Zhou S; Sun H; Choi SI; Yin J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
[TBL] [Abstract][Full Text] [Related]
25. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
26. CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.
Zhang XW; Wu YS; Xu TM; Cui MH
Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400
[TBL] [Abstract][Full Text] [Related]
27. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
28. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
30. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
31. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
Stock S; Schmitt M; Sellner L
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
[TBL] [Abstract][Full Text] [Related]
32. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
33. [Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy].
Holzinger A; Abken H
Internist (Berl); 2021 Jun; 62(6):583-588. PubMed ID: 33928413
[TBL] [Abstract][Full Text] [Related]
34. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Holland EM; Yates B; Steinberg SM; Yuan CM; Wang HW; Annesley C; Shalabi H; Stroncek D; Fry TJ; Krueger J; Jacoby E; Hsieh E; Bhojwani D; Gardner RA; Maude SL; Shah NN
Transplant Cell Ther; 2023 Sep; 29(9):574.e1-574.e10. PubMed ID: 37394115
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
37. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
Yu YD; Kim TJ
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
[TBL] [Abstract][Full Text] [Related]
39. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
